Amicus Therapeutics (NASDAQ:FOLD) Downgraded by StockNews.com to “Hold”

StockNews.com downgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a hold rating in a research note issued to investors on Monday.

Other analysts have also issued reports about the stock. Guggenheim raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald raised their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Morgan Stanley decreased their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, Bank of America raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $9.96 on Monday. Amicus Therapeutics has a 1 year low of $9.02 and a 1 year high of $14.57. The firm’s fifty day simple moving average is $10.70 and its 200 day simple moving average is $10.60. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $2.98 billion, a PE ratio of -29.29 and a beta of 0.68.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 22,901 shares of company stock valued at $264,213. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors have recently added to or reduced their stakes in FOLD. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics during the 3rd quarter valued at about $26,000. Hazlett Burt & Watson Inc. lifted its holdings in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Blue Trust Inc. lifted its holdings in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI bought a new position in shares of Amicus Therapeutics in the third quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Amicus Therapeutics in the third quarter worth about $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.